Jan. 8 at 2:45 AM
$ALT $XBI These are early days in the growth of the burgeoning MASH and Cardiometabolic diseases space. Resmetirom received BTD only two and three quarters YR ago on the day MDGL announced the last patient received initial P3 dosing.
By contrast, Lipitor was brought to market by Warner Lambert (
$PFE acquisition) almost 10 years AFTER
$MRK Mevacor (Lovastatin) had became the first statin drug to reach market.
There will be millions of diverse patients globally in need of MASH and Cardiometabolic Disease treatment options in the years ahead.
Breakthrough Therapy Designation, with this serious a disease & unmet medical need and at this scale of a patient population, is in my opinion part of an intangible asset profile both scientifically and financially that has many-fold greater intrinsic potential value than the currently pinned sub 500M mcap (to state the obvious).
Disclosure: Long Altimmune (Pemvi GCGR), not medical / investment advice.
